GlobeNewswire

Enhesa Announces the Increase in Global Jurisdiction Coverage to 286 in 2018, and Celebrates Being Named to CIO Review's 20 Most Promising Compliance Technology Solution Providers

Dela

Brussels, Belgium, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Enhesa, the leading global content provider focused on environmental, health and safety (EHS) regulatory compliance assurance support to industries worldwide, just announced the increase in global jurisdiction coverage for 2018 to reach up to 286.

Enhesa supports the Global EHS programs for many of the world's largest companies by offering a standardized, consistent suite of services enabling them to be aware of, and stay in compliance with, EHS laws wherever they operate. As a result, today, Enhesa offers off-the-shelf services in an impressive 286 jurisdictions.

New additions to the Enhesa geographic catalogue in 2018 (in English) include the following jurisdictions:

  • Argentina - Chaco
  • Argentina - Chubut
  • Azerbaijan
  • Burkina Faso
  • Canada - Northwest Territories
  • China - Guizhou
  • China - Hainan
  • China - Heilongjiang
  • Ecuador
  • German - Hanseatic City of Bremen
  • Germany - Mecklenburg - Western Pomerania
  • India Dadra -Nagar Haveli
  • India - Rajasthan
  • Macao
  • Malawi
  • Pakistan - Sindh
  • Slovenia
  • Switzerland - Solothurn
  • Switzerland - Vaud
  • Turkmenistan

Enhesa has also increased coverage by providing local language versions for the following jurisdictions:

  • Argentina - Chaco
  • Brazil - Alagoas
  • Brazil - Amazonas
  • Brazil - Maranhao
  • Brazil - Mato Grosso
  • Brazil - Parana
  • Brazil - Pernambuco
  • China - Fujian
  • China - Guizhou
  • China - Hainan
  • China - Heilongjiang
  • Guinea - National
  • Macao
  • Mali
  • Mexico - Chiapas
  • Mexico - Michoacan
  • Mexico - Quintana Roo
  • Mexico - Tlaxcala
  • Morocco
  • Paraguay
  • UAE - Abu Dhabi

Peter Hermans, Enhesa CEO further points out: "We are extremely proud of the truly global coverage we are able to offer our multinational clients. But our commitment to supporting our clients does not stop here. We will continue to partner with our current and future clients to expand our coverage as their presence around the world spreads, and provide them with the tools they need to manage EHS legal compliance at the corporate, regional, divisional and site levels."

In addition, Enhesa was selected, along with 19 other companies, to appear on CIO Review's list of "20 Most Promising Compliance Technology Solution Providers" for 2017. To help CCOs, CIOs, and CEOs find the right compliance technology provider for their enterprises, CIO Review's selection panel evaluated and shortlisted hundreds of compliance technology solution providers that are at the forefront of providing cutting-edge technology solutions.

Enhesa provides time-saving, simplified regulatory analysis translated by our in-house team of analysts - who represent approximately 45 nationalities around the world. This is why Enhesa is the leading solution to regulatory compliance forecasting and intelligence that will save you ample time and money.

To find out more about how Enhesa can help support your global EHS compliance program, please visit enhesa.com.


Company Description:

Enhesa helps global multinational companies be compliant with, and stay on top of, Environmental, Health & Safety (EHS) Regulations wherever they operate.

Enhesa's in-house team of multilingual regulatory analysts provide clear, concise and standardized content and insight on current and future EHS regulatory obligations in over 285 jurisdictions worldwide.

Enhesa's Compliance Intelligence and Regulatory Forecaster services can be provided as an automated data feed - integrated with the world's leading EHS software platforms.

Enhesa has offices in Brussels, Washington DC and Tokyo.

For more information, please visit enhesa.com or email info@enhesa.com

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ce76d13c-c729-4af3-a523-e61b4b7cc362

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1ecae2c0-6ed0-45a7-916c-f29b8c68eb53

Gloria Johnston
Enhesa
202-552-1090 ext. 203
gj@enhesa.com

Allison Gilmore
Enhesa
202-552-1090 ext. 242
agil@enhesa.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enhesa via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum